AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12645831
Drug: Sequential i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential i.v. ceftriaxone/oral cefuroxime
Trial: 8879372
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg twice a day
Trial: 28592620
Drug: Trebananib 10
RxNorm normalized name: Trebananib
DrugBank: Trebananib (DB12056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib 10 mg/kg plus sorafenib 400 mg orally twice daily
Trial: 28592620
Drug: Trebananib 15
RxNorm normalized name: Trebananib
DrugBank: Trebananib (DB12056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib 15 mg/kg plus sorafenib 400 mg orally twice daily
Trial: 8181192
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily for 1 week)
Trial: 23331498
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg)
Trial: 18355218
Drug: Home visiting
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home visiting (treatment as usual)
Trial: 16931678
Drug: Valdecoxib 20
RxNorm normalized name: valdecoxib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 20 mg every 12 h for 72 h postoperatively
Trial: 12788192
Drug: Pilocarpine 5
RxNorm normalized name: PILOCARPINE 5MG/UNT OPH,CRC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine 5 mg
Trial: 17426226
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol
Trial: 11119400
Drug: Routine antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotic treatment
Trial: 11119400
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of patient and physician education
Trial: 2885853
Drug: Astemizole suspension
RxNorm normalized name: Astemizole
DrugBank: Astemizole (DB00637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Astemizole suspension (5 ml, 1 mg/ml) once daily
Trial: 2885853
Drug: Terfenadine suspension
RxNorm normalized name: terfenadine Oral Suspension
DrugBank: Terfenadine (DB00342)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terfenadine suspension (5 ml, 6 mg/ml) twice daily
Trial: 23410501
Drug: Back massage
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back massage therapy (20 minutes session for 5 consecutive days)
Trial: 22236804
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n = 16)
Trial: 30779100
Drug: Oral diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diet (OD)
Trial: 11073745
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (3 mg/kg/d)
Trial: 1312797
Drug: Mexiletine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (750 mg/day)
Trial: 2996726
Drug: Pindolol (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5-10 mg twice a day)
Trial: 2996726
Drug: Propranolol (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40-80 mg 4 times a day)
Trial: 31343376
Drug: DMSO‐L (local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSO‐L (local administration)
Trial: 31343376
Drug: DMSO‐IP (intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSO‐IP (intraperitoneal administration)
Trial: 31279564
Drug: MenACWY-CRM (booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (booster dose)
Trial: 25744224
Drug: MenACWY-CRM (primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (primary dose)
Trial: 21512577
Drug: Two double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two double doses of influenza vaccine over 28 days
Trial: 21512577
Drug: Single standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single standard dose of influenza vaccine
Trial: 14872039
Drug: Phenobarbitone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone (40 mg/kg as first line)
Trial: 10714475
Drug: 5-day moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day moxifloxacin 400 mg once daily
Trial: 9324147
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid (IVF), n = 17
Trial: 2412521
Drug: Monoamine oxidase
RxNorm normalized name: Monoamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine oxidase inhibitor (N=9)
Trial: 25158287
Drug: Caffeinated energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated energy drink (3 mg caffeine per kg body mass)
Trial: 21600090
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose chemotherapy plus valproic acid (VPA)
Trial: 21600090
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose chemotherapy regimen
Trial: 18329827
Drug: Medication clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication clinic only
Trial: 18329827
Drug: Medication clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication clinic plus BRENDA
Trial: 18329827
Drug: Medication clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication clinic plus cognitive behavioral therapy (CBT)
Trial: 10934074
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI)
Trial: 12511312
Drug: High-dose albuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose albuterol (15 mg/hr)
Trial: 12511312
Drug: Usual-dose albuterol
RxNorm normalized name: albuterol Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-dose albuterol (7.5 mg/hr)
Trial: 10371571
Drug: Subcutaneous interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interleukin-2 (3 million IU/m2 twice daily for 5 days)
Trial: 1650528
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvant chemotherapy (CAV) plus intrapleural BCG
Trial: 6868628
Drug: Percutaneous high‐voltage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous high‐voltage therapy with cobalt 60 (51 patients)
Trial: 26388169
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg oxantel pamoate
Trial: 30745388
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg oxantel pamoate
Trial: 22590991
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg iron and 250 µg folate with or without 15 mg zinc
Trial: 11902732
Drug: IFN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN plus Ara‐C (5 million units/m2 IFN once per day and 20 mg/m2 Ara‐C for 10 days each month)
Trial: 2151889
Drug: Enoximone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (0.5 mg/kg)
Trial: 19017758
Drug: Detemir once
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Detemir once daily and aspart before meals (n = 67)
Trial: 17523932
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during 4 weeks of TL01 therapy
Trial: 17523932
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite 400 microg daily
Trial: 6653683
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (SRT)
Trial: 2455107
Drug: Felodipine 2.5
RxNorm normalized name: felodipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 2.5 mg b.i.d.
Trial: 2455107
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg b.i.d.
Trial: 2455107
Drug: Felodipine 10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 10 mg b.i.d.
Trial: 6202963
Drug: Felodipine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (all doses)
Trial: 12972722
Drug: no interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no interval treatment for 12 weeks followed by semi-standardized acupuncture (75 patients, waiting list control)
Trial: 8769387
Drug: Sandostatin LAR
RxNorm normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sandostatin LAR (20 mg and 30 mg doses at 4-week intervals)
Trial: 1413981
Drug: Diuretic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic and possibly a beta-blocker or reserpine (active treatment group)
Trial: 31331587
Drug: Methylsulfonylmethane (MSM)
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylsulfonylmethane (MSM) 6g daily
Trial: 23546629
Drug: Bufei Yishen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bufei Yishen Granule combined with Shufei Tie acupoint sticking therapy
Trial: 20884928
Drug: Mucoadhesive disks
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucoadhesive disks (OraMoist) applied three times daily
Trial: 20884928
Drug: Placebo mucoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mucoadhesive disks applied three times daily
Trial: 15669885
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 to 150 mg/day
Trial: 17413099
Drug: Lower-protein (LP)
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-protein (LP) group; 0.9 g protein . kg(‐1) . d(‐1)
Trial: 15492337
Drug: Ciprofloxacin, 500
RxNorm normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg twice daily
Trial: 11444447
Drug: Epidural normal
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural normal saline followed by iv 2% lidocaine (0.05 mL.kg(‐1)) then propofol
Trial: 321183
Drug: sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulindac 200 mg twice daily
Trial: 17297383
Drug: Rifalazil 25
RxNorm normalized name: Rifalazil
DrugBank: Rifalazil (DB04934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifalazil 25 mg
Trial: 17297383
Drug: Azithromycin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1.0 g
Trial: 15385119
Drug: 0.3 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/m2 daily for 5 days every 3 weeks (Arm A)
Trial: 15385119
Drug: 2.1 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.1 mg/m2 weekly for 3 weeks out of 4 (Arm B)
Trial: 8005182
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg tds)
Trial: 31863406
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy plus migraine education (ACT-ED)
Trial: 29092982
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus of 20 mg/kg IV TXA before incision (group A)
Trial: 29092982
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus followed by a second bolus of 1 g IV TXA three hours later (group B)
Trial: 29092982
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus followed by two boluses of 1 g IV TXA three and six hours later (group C)
Trial: 23200803
Drug: Cardioselective β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioselective β blockers
Trial: 18381090
Drug: Support for
RxNorm normalized name: GNP Diabetic Support Formula Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Support for clinical trials and drug development
Trial: 12761013
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 mL normal saline)
Trial: 11061604
Drug: Cisplatin-etoposide-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-etoposide-based chemotherapy
Trial: 31219248
Drug: Ertugliflozin/Sitagliptin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin/Sitagliptin FDC tablet (5 mg/50 mg)
Trial: 31219248
Drug: Ertugliflozin/Sitagliptin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin/Sitagliptin FDC tablet (5 mg/100 mg)
Trial: 31219248
Drug: Ertugliflozin/Sitagliptin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin/Sitagliptin FDC tablet (15 mg/50 mg)
Trial: 31219248
Drug: Ertugliflozin/Sitagliptin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin/Sitagliptin FDC tablet (15 mg/100 mg)
Trial: 28543263
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g mesalazine once daily (SAG-51)
Trial: 28543263
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g mesalazine once daily (SAG-51)
Trial: 21114549
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg karaya saponin
Trial: 21114549
Drug: 75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/kg karaya saponin
Trial: 18165565
Drug: Ketamine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.75 mg/kg
Trial: 7888516
Drug: Meperidine 25
RxNorm normalized name: meperidine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 25 mg
Trial: 14673011
Drug: methylphenidate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylphenidate (0.5 mg/kg, i.v.)
Trial: 8412414
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg d-fenfluramine
Trial: 8412414
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg l-fenfluramine
Trial: 23298079
Drug: Hydrogel injection
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel injection
Trial: 12802837
Drug: Self-administered medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered medication program
Trial: 12802837
Drug: Nurse-administered medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered medications
Trial: 12378376
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for hypertension in macroalbuminuric patients
Trial: 12378376
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of more than one anti-hypertensive drug
Trial: 16858168
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of ACE inhibitors
Trial: 28353056
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg oral psilocybin
Trial: 28353056
Drug: 0.45 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/kg oral psilocybin
Trial: 28353056
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg oral psilocybin
Trial: 23407049
Drug: First-line monotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line monotherapy capecitabine
Trial: 23407049
Drug: Capecitabine-irinotecan combination
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine-irinotecan combination therapy
Trial: 16735941
Drug: EA 1.8
RxNorm normalized name: Anti-Nausea 1.87g-1.87g-21.5mg/5mL Liquid (Cherry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA 1.8 mg/day
Trial: 16735941
Drug: EA 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA 0.9 mg/day
Trial: 16735941
Drug: EA 0.45
RxNorm normalized name: urea 0.45 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA 0.45 mg/day
Trial: 16735941
Drug: EA 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA 0.9 mg/day and EA 1.8 mg/day
Trial: 31942927
Drug: Control (placebo)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (placebo) treatment
Trial: 26813845
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (CBTi)
Trial: 18992162
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy (RT)
Trial: 16531163
Drug: ethinylestradiol 30
RxNorm normalized name: Drospirenone 3 mg and ethinylestradiol 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethinylestradiol 30 mug/drospirenone 3 mg (EE/DRS)
Trial: 10950230
Drug: Malathion lotion
RxNorm normalized name: Malathion Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malathion lotion (0.5%) applied twice, 7 days apart
Trial: 8825255
Drug: Integrated service
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated service agencies (ISAs) with financing reform and assertive continuous treatment team approach
Trial: 1563207
Drug: Bidisomide (SC-40230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bidisomide (SC-40230) intravenous doses ranging from 0.03 to 2.5 mg/kg
Trial: 1563207
Drug: Bidisomide (SC-40230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bidisomide (SC-40230) 2.0 mg/kg orally and intravenously
Trial: 6362417
Drug: Extraperitoneal cesarean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraperitoneal cesarean section plus prophylactic antibiotics (group C)
Trial: 25683592
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg daily)
Trial: 31066956
Drug: Urethral bulking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral bulking therapy
Trial: 22964561
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy (DBT) for 12 months
Trial: 22964561
Drug: DBT (completed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBT (completed treatment)
Trial: 17928325
Drug: Albendazole 15
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 15 mg/kg/day for 2 weeks
Trial: 17928325
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cysticidal therapy)
Trial: 8556997
Drug: Rocuronium as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium as a priming agent
Trial: 8556997
Drug: Rocuronium and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium and vecuronium as priming agents
Trial: 1930849
Drug: 15 mmol
RxNorm normalized name: dibasic potassium phosphate 15 MMOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mmol Mg added to a free diet for 6 months
Trial: 19700248
Drug: Conventional (tangential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional (tangential field) fractionated whole breast treatment (Arm A)
Trial: 15833589
Drug: Cortisol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (0.5 mg/kg)
Trial: 7759146
Drug: BioLogic-DT sorbent
RxNorm normalized name: L-DT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BioLogic-DT sorbent suspension dialyser
Trial: 2856651
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human growth hormone releasing factor (hGRF) (1 microgram/kg in 5 cc of normal saline infused over five minutes)
Trial: 2856651
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human growth hormone releasing factor (hGRF)
Trial: 30965599
Drug: BoNT‐A combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A combined with a four‐week ankle isokinetic treatment (n = 12)
Trial: 2328112
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (3 drops, 250 micrograms/mL in saline solution) locally twice a day (group B)
Trial: 2328112
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of topical ciprofloxacin and oral ciprofloxacin (group C)
Trial: 2328112
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (250 mg orally twice a day) (group A)